Advances in Alopecia Areata Treatment: Ritlecitinib and Deuruxolitinib

Recent studies have highlighted significant advancements in the treatment of alopecia areata, an autoimmune condition characterized by sudden hair loss. Two notable drugs, ritlecitinib (Litfulo; Pfizer) and deuruxolitinib (Leqselvi; Sun Pharma), have emerged as effective options for patients with moderate to severe forms of the disease.

Deuruxolitinib in the Alopecia Areata Treatment Paradigm: Emma Guttman-Yasskey, MD

Ritlecitinib, a JAK3/TEC kinase inhibitor, has shown promise in reshaping immune responses in the scalp while promoting hair growth. The findings from the ALLEGRO-2a clinical trial indicated that treatment led to a significant correlation between changes in immune activity and hair regrowth. Specifically, the study found that after 12 weeks of treatment, genes associated with hair growth were reactivated, while those driving autoimmune responses were suppressed. This dual action resulted in notable improvements in patients with patchy alopecia areata, while those with more extensive forms, such as alopecia totalis and universalis, experienced slower regrowth.

Ritlecitinib Spurs Hair Regrowth in Alopecia AreataDeuruxolitinib in the Alopecia Areata Treatment Paradigm: Emma Guttman-Yasskey, MD8 hair loss 'cures' that actually worsen balding in boomers—and what works instead

The study also identified potential biomarkers that could predict treatment success. Patients exhibiting higher expression of hair keratin genes and lower inflammatory gene expression at the trial's onset were more likely to achieve hair regrowth. However, the study's limitations included a small patient cohort and a follow-up period of only 24 weeks, suggesting that further research is necessary to fully understand ritlecitinib's long-term efficacy.

Ritlecitinib Spurs Hair Regrowth in Alopecia AreataDeuruxolitinib in the Alopecia Areata Treatment Paradigm: Emma Guttman-Yasskey, MD8 hair loss 'cures' that actually worsen balding in boomers—and what works instead

Deuruxolitinib, an oral selective inhibitor of JAK1 and JAK2, received FDA approval in 2024 following successful trials (THRIVE-AA1 and THRIVE-AA2). The drug demonstrated a high percentage of hair regrowth, particularly at the 8 mg dosage, which was noted for its rapid efficacy compared to other treatments. Emma Guttman-Yassky, MD, emphasized the importance of fast hair regrowth for patients, particularly in contexts such as weddings or school events.

Deuruxolitinib in the Alopecia Areata Treatment Paradigm: Emma Guttman-Yasskey, MDRitlecitinib Spurs Hair Regrowth in Alopecia Areata8 hair loss 'cures' that actually worsen balding in boomers—and what works instead

However, prescribing deuruxolitinib requires genetic testing, which adds a layer of complexity to its administration. This necessity for testing means that healthcare providers must manage patient expectations regarding the timeline for treatment initiation.

Deuruxolitinib in the Alopecia Areata Treatment Paradigm: Emma Guttman-Yasskey, MD

Despite the promising results associated with both ritlecitinib and deuruxolitinib, there are concerns regarding the long-term safety profiles of these JAK inhibitors. Adverse events, including pulmonary emboli and deep vein thrombosis, were noted in trials, necessitating ongoing monitoring of patients.

Deuruxolitinib in the Alopecia Areata Treatment Paradigm: Emma Guttman-Yasskey, MD

Future studies are essential to validate the identified biomarkers and assess treatment effects beyond the initial 24 weeks. Researchers aim to employ advanced technologies, such as RNA sequencing, to further explore the interactions between immune cells and hair follicles during treatment.

Ritlecitinib Spurs Hair Regrowth in Alopecia Areata

• “Following treatment with ritlecitinib, CFB in type I and II immunity and hair growth gene expression levels in lesional scalp at week 12 correlated significantly with disease improvement (scalp hair regrowth) at week 24, suggesting that early molecular response is linked to clinical response,” — Researchers, Allergy Journal

Ritlecitinib Spurs Hair Regrowth in Alopecia Areata

• “Upon treatment with ritlecitinib, the significant correlation between changes in expression levels of JAK3, ITK, and BTK (ritlecitinib mechanistic targets) and disease improvement indicates that effective targeting and modulation of these genes are important for response to ritlecitinib treatment,” — Researchers, Allergy Journal

Ritlecitinib Spurs Hair Regrowth in Alopecia Areata

• “They want to achieve fast hair regrowth, and they want to maintain it over time.” — Emma Guttman-Yassky, MD, Icahn School of Medicine

Deuruxolitinib in the Alopecia Areata Treatment Paradigm: Emma Guttman-Yasskey, MD

In conclusion, the advancements in alopecia areata treatments through ritlecitinib and deuruxolitinib offer new hope for patients, although further research is necessary to optimize their use and understand their long-term implications.

Deuruxolitinib in the Alopecia Areata Treatment Paradigm: Emma Guttman-Yasskey, MD